Maverick Capital, Ltd. 13D and 13G filings for Rocket Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-13 4:10 pm Sale | 2025-12-31 | 13G | Rocket Pharmaceuticals, Inc. RCKT | Maverick Capital, Ltd. | 2,513,110 2.300% | -5,850,703 (-69.95%) | Filing |
| 2025-08-14 08:00 am Purchase | 2025-06-30 | 13G | Rocket Pharmaceuticals, Inc. RCKT | Maverick Capital, Ltd. | 8,363,813 7.800% | 2,816,638 (+50.78%) | Filing |
| 2025-04-14 5:10 pm Purchase | 2025-04-07 | 13G | Rocket Pharmaceuticals, Inc. RCKT | Maverick Capital, Ltd. | 5,547,175 5.200% | 5,547,175 (New Position) | Filing |